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Abstract
Background: Interleukin (IL)-17 is an important factor in rheumatoid arthritis (RA) pathogenesis. MicroRNA (miRNA)s
are a family of non coding RNAs and associated with human diseases including RA. The purpose of this study is to
identify the miRNAs in the differentiation of IL-17 producing cells, and analyze their expression pattern in the
peripheral blood mononuclear cells (PBMC) and synovium from RA patients.
Methods: IL-17 producing cells were expanded from CD4+T cell. MiRNA microarray was performed to identify the
miRNAs in the differentiation of IL-17 producing cells. Quantitative polymerase chain reaction was performed to
examine the expression patterns of the identified miRNAs in the PBMC and synovium from RA and osteoarthritis
(OA) patients. Double staining combining in situ hybridization and immunohistochemistry of IL-17 was performed
to analyze the expression pattern of identified miRNA in the synovium.
Results: Six miRNAs, let-7a, miR-26, miR-146a/b, miR-150, and miR-155 were significantly up regulated in the IL-17
producing T cells. The expression of miR-146a and IL-17 was higher than in PBMC in the patients with low score of
Larsen grade and short disease duration. MiR-146a intensely expressed in RA synovium in comparison to OA. MiR-
146a expressed intensely in the synovium with hyperplasia and high expression of IL-17 from the patients with
high disease activity. Double staining revealed that miR-146a expressed in IL-17 expressing cells.
Conclusion: These results indicated that miR-146a was associated with IL-17 expression in the PBMC and synovium
in RA patients. There is the possibility that miR-146a participates in the IL-17 expression.
Background
Rheumatoid arthritis (RA) is characterized by chronic
synovial inflammation and subsequent joint destruction
[1]. The infiltration of macrophages, T cells and B cells in
RA synovium plays a crucial role in RA pathogenesis
including proliferation of the lining cells, and production
of inflammatory cytokines such as tumor necrosis factor-
(TNF-)a, and interleukin-1- (IL-1-)b. However, the
pathogenesis of RA has not been completely elucidated.
The discovery of a new linage of CD4+ effector
T helper type17 cells (Th17cells) that selectively pro-
duce IL-17 has provided exciting new insights into
immune regulation, host defense, and pathogenesis of
autoimmune and other chronic inflammatory disorders
including of RA [2-4]. IL-17 is a proinflammatory
cytokine, which induces other cytokines, such as TNFa,
IL-1b,I L - 6 ,I L - 2 3a n dG - C S F[ 5 - 8 ] .I na d d i t i o n ,I L - 1 7
plays a role in osteoclastogenesis via activation of
RANKL(receptor activator of NF-B ligand), causing
bone destruction in inflammatory joints [9-11]. Several
studies demonstrated that IL-17 is higher in synovial
fluid, synovium and peripheral blood mononuclear cells
in RA patients than that in healthy subjects [12-14].
IL-17 is recognized to be the one of the important fac-
tors in RA pathogenesis.
MicroRNA (miRNA)s are a family of ~22-nucleotide
non coding RNAs identified in organisms ranging from
nematodes to humans [15-17]. Many miRNAs are evo-
lutionarily conserved across phyla, thereby regulating
gene expression by posttranscriptional gene repression.
T h em i R N A sr e g u l a t eg e n ee x p r e s s i o nb yb i n d i n gt h e
3′-untranslated region of their target mRNAs leading
to translational repression or mRNA degradation
[18-21]. Several microRNAs exhibit a tissue-specific or
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have been reported to be associated with human dis-
eases such as cancer, leukemia, and viral infection
[22,23]. These findings suggest their potential as a
novel therapeutic target. miRNA might play a role in
RA pathogenesis in autoimmune and other chronic
inflammatory diseases including of RA. Several studies
reported that miRNA might play a role in RA patho-
genesis. Stancyzk et al. reported that miR-146 and
miR-155 are highly expressed in RA synovial fibroblast
in comparison to osteoarthritis fibroblast [24]. Nakasa
et al. demonstrated that miR-146 is highly expressed in
RA synovial tissue in comparison to OA and normal
synovial tissue. They also revealed that miR-146 is
expressed primarily in CD68+ macrophages, but also
in some CD3+ T cell subsets and CD79a+ B cells in
RA synovial tissue [25]. Paulay et al. reported that
PBMCs from RA patients exhibit statistically signifi-
cant increase the expression levels of miR-146a, miR-
155, miR-132, and miR-16 in comparison to healthy
and disease control individuals. They also demon-
strated that high levels of miR-146a and miR-16
expression correlate with active disease, whereas low
expression levels correlate with inactive disease [26].
Changsheng Du et al. reported that miR-326 regulates
Th-17 differentiation and associated with the patho-
genesis of multiple sclerosis[27]. These findings suggest
that miRNA also might play a role in the expression of
IL-17, and an analysis of the expression pattern of
miRNAs in IL-17 producing T cells might lead to the
development of new treatments for RA.
The purpose of this study is to identify miRNAs in the
differentiation of IL -17 producing T cells, and to ana-
lyze their expression pattern in the RA patients. MiR-
NAs were identified during the differentiation of IL-17
producing T cells by the expansion from healthy CD4+
T cells using microarray analysis, and analyzed the
expression pattern of the identified miRNAs in the per-
ipheral blood mononuclear cells (PBMC) and synovium
from RA and OA patients.
Methods
Patients
This clinical study was approved by the University of Hir-
oshima Institutional Review Board, and written permission
was obtained from all patients who participated in this
study. Peripheral blood was taken from 6 RA patients
(67.3 ± 8.02 years of age, mean ± standard deviation (SD))
and 6 OA patients (75.3 ± 5.0 years of age, mean ± SD).
They were diagnosed according to the American Rheuma-
tism Association Criteria for RA or OA[28]. Synovial tis-
sue specimens were obtained at the time of total knee
arthroplasty on 4 RA patients and two RA patients
(RA8,RA9) were obtained at the time of synovectomy
(67.7 ± 10.4 years of age, mean ± SD). All OA synovial
tissue samples were obtained by total knee arthroplasty
(74 ± 5.1 years of age, mean ± SD). Patient RA3 and RA5
showed more erosive disease, with severe destruction in
the large joints. They underwent total knee arthroplasty
before, and they were subsequently well controlled. The
disease in patients RA1, RA2 and RA4 were poorly con-
trolled, but soft tissue swelling, juxta-articular osteopenia,
and loss of joint space were observed. Patient RA6, RA7,
RA10 and RA11 showed more erosive disease, with severe
destruction in the large joints. RA8 and RA9 had the least
erosive disease. In addition, 6 patients with knee osteo-
arthritis (OA) diagnosed according to typical clinical
features. The demographics of the RA and OA patients
are listed in Table 1.
Cell isolation and expansion of IL-17 producing T cells
This clinical study was approved by the University of
Hiroshima Institutional Review Board, and written per-
mission was obtained from all healthy volunteers who
participated in this study. Human peripheral blood was
collected from 5 healthy volunteers (31.8 ± 1.1 years of
age, mean ± SD) into DPBS-E (5 mM: 0.5 M EDTA)
drop by drop and mixed well. This mixture was loaded
slowly onto Histopaque® (Sigma Chemical Co. CA) in
another tube, and centrifuged at 1000 × g at room tem-
perature for 10 min. PBMC accumulated as the middle
white monolayer. After the supernatant was discarded,
only the white monolayer cells were aspirated and put
into DPBS-E, then centrifuged at 400 × g at 4°C for
10 min. The supernatant was discarded, DPBS-E and
ammonium chloride (The cell Experts™) were added at
the rate of 1:3, and the mixture was allowed to stand at
room temperature for 10 min. After centrifuging at
400 × g at 4°C for 10 min, supernatant was discarded,
a n dD P B S - Ew a sa d d e da n dm i x e dw e l l .T h i sf i n a lp r o -
cess was repeated several times. The remaining white
cells were peripheral blood mononuclear cells (PBMC).
CD4+ T cells were isolated from PBMC using auto
MACS (CD4+T cell Isolation kit, Miltenyi Biotec,). IL-
17 producing cells were expanded from CD4+ T cells as
previously described [29]. PBMC or purified CD4+
T cells (1 × 10
6 per ml) were re-suspend in fresh culture
medium containing requisite antibiotics and serum plus
IL-2 (100 u/ml), IL -1 b, IL-2, IL -6 and IL -23 (R&D
Systems; 10ng/ml). The cells were cultured in 24 well
plates (2 ml per well) at 37°C for 4 days in 5% CO2.
Afterwards, IL-17 expression was confirmed with
R T - P C Ra n dE L I S A ,a n dt h ep r e s e n c eo fI L - 1 7p r o d u -
cing T cells was also confirmed (data is not shown).
Tissue samples
Three synovial tissue specimens per one patient were
obtained from random sites during surgery. Each was
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inflammatory tissue. Tissues were stored at -70°C until
analysis. Total RNA for the PCR analysis was isolated
from tissues homogenized with Trizol (Invitrogen) on
ice for. The tissue specimens were fixed in 4% parafor-
maldehyde and paraffin-embedded for histopathological
analysis.
Microarray analysis
miRNA microarrays (NCode microarray, Invitrogen)
were performed for the identification of miRNA in dif-
ferentiating IL-17 producing cells. The dual-color dye
swap method was used to analyze differences of miRNA
expression between expanded IL-17 producing cells and
non-expanded cells. Five-hundred nanograms of the
enriched miRNA was labeled with the NCode Rapid
miRNA labeling kit (Invitrogen) and hybridized to
NCode multispecies miRNA arrays as described earlier
based on a loop design, balanced with respect to array,
dye, and sample. The balanced design minimized
sources of unwanted variation. The arrays were scanned,
aligned, and median spot intensities were obtained using
a GenePix 4000B scanner (Molecular Devices, Inc., Sun-
nyvale, CA, USA).
Synthesis of complementary DNA
One microgram of total RNA was reverse-transcribed
using the QuantiTect® Reverse Transcription Kit (Qia-
gen, Chatsworth, CA) according to the manufacturer’s
protocol. The genomic DNA elimination reaction was
carried out using 2 μl of gDNA wipeout buffer, 1 μg
(1 μl) template RNA and 11 μl RNase-free water at 42°C
for 2 min. Reverse transcription was performed in 1 μl
quantiscript reverse transcriptase, 4 μl quantiscript RT
buffer, 1 μlR Tp r i m e rm i xa n d1 4μl template RNA
(the entire genomic DNA elimination reaction) at 42°C
for 15 min and 95°C for 3 min and then the cDNA
product was maintained at 4°C.
Quantitative (real time) PCR
Quantitative RT-PCR assays were performed using a Taq-
Man miRNA assay kit (Applied Biosystems, CA, USA) for
the expression of miRNAs and SYBR Green (Invitrogen)
for the expression of IL-17, Foxp3, retinoid-related orphan
receptor gt( R O R gt), IL-1 receptor-associated kinase
1(IRAK1) and suppressor of cytokine signaling 1(SOCS1).
Reverse transcriptase reactions of mature miRNAs con-
tained a sample of total RNA, 50 nM stem-loop RT pri-
mer, 10 × RT buffer, 100 mM each dNTPs, 50 U/μl
Table 1 Demographic and clinical features of this study subjects
disease duration Larsen grade K/L
score
CRP ESR synovium
subject age sex RF PBMC medication
(yr) for RA for OA (mg/ml) (mm/hr) (source)
RA1 76 F 4 Ⅰ 0.53 45 209.3 ○ MTX, NSAIDs
RA2 69 M 3 Ⅱ 0.31 52 22.9 ○ bucillamine, NSAIDs
RA3 59 M 16 Ⅴ 3.53 no data 49.5 ○ MTX, predonisone, NSAIDs
RA4 59 F 2 Ⅰ 4.12 74 129.2 ○ salazosulfapyridine
RA5 64 M 17 Ⅴ 2.57 48 65.3 ○ bucillamine, NSAIDs
RA6 77 F 3 Ⅳ 0.16 66 160.9 ○○ (knee) salazosulfapyridine
RA7 63 F 14 Ⅳ 0.33 21 <6.0 ○ (knee) infliximab
RA8 54 M 3 Ⅲ 3.07 no data no data ○ (elbow) MTX, predonisone, NSAIDs
RA9 79 M 5 Ⅲ 0.03 8 6.1 ○ (wrist) NSAIDs
RA10 74 F 15 Ⅳ 0.33 27 no data ○ (knee) bucillamine, NSAIDs
RA11 59 F 5 Ⅳ 3.55 61 60.8 ○ (knee) MTX, bucillamine, predonisone, NSAIDs
OA1 74 F Ⅳ ○ NSAIDs
OA2 78 F Ⅳ ○○ (knee) NSAIDs
OA3 83 F Ⅳ ○○ (knee) NSAIDs
OA4 71 F Ⅲ ○ (knee) NSAIDs
OA5 76 M Ⅳ ○ NSAIDs
OA6 70 F Ⅳ ○ NSAIDs
OA7 71 F Ⅳ ○ NSAIDs
OA8 74 F Ⅳ ○ (knee) NSAIDs
OA9 70 F Ⅳ ○ (knee) NSAIDs
OA10 71 F 　　 Ⅳ 　　　　 ○ (knee) NSAIDs
RA : rheumatoid arthritis; OA : osteoarthritis; K/L : Kellgren/Lawrence; CRP : C-reactive protein; ESR : erythrocyte sediment rate; RF : rheumatoid factor; MTX :
methotrexate; NSAIDs : nonsteroidal anti-inflammatory drugs;
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bitor. 15 μl reactions were incubated in a thermo cycler
(BioRad) for 30 min at 16°C, 30 min at 42°C, 5 min at
85°C, and held at 4°C. Real time PCR was performed using
a Mini Opticon Real-time PCR System (BioRad, Hercules,
CA) in a 10 μlP C Rm i x t u r ec o n t a i n i n g1 . 3 3μlR Tp r o -
duct, 2 × TaqMan Universal PCR Master Mix, 0.2 μM
TaqMan probe, 15 μMf o r w a r dp r i m e r ,a n d0 . 7μM
reverse primer. Each SYBR Green reaction was performed
with 1.0 μl template cDNA, 10 μl SYBR Green mix,
1.5 μM primer, and water to adjust the final volume to
20 μl. Primer sequences were: IL-17, 5′- AAG ACC TCA
TTG GTG TCA CTG CT AC-3′(forward), 5′- ATC TCT
CAG GGT CCT CAT TGC G-3′ (reverse); Foxp3, 5′-
GAG AAG CTG AGT GCC ATG CA -3′(forward), 5′-
AGA GCC CTT GTC GGA TGA T -3′(reverse); RORgt,
5′- TGA GAA GGA CAG GGA GCC AA-3′(forward), 5′-
CCA CAG ATT TTG CAA GGG ATC A -3′ (reverse);
SOCS1, 5′- GAA CTG CTT TTT CGC CCT TA -3′(for-
ward), 5′- CTC GAA GAG GCA GTC GAA G -3′
(reverse); IRAK1, 5′- GCT CTT TGC CCA TCT CTT TG
-3′(forward), 5′- GCT ACC ACG CCA GGC TAA TA -3′
(reverse); GAPDH, 5′- AAG AAT TGC AAG TCT ACA
TAT CAC CCA AG. -3′(forward), 5′- GGT CAT GGT
CAC AGA GCC ACC-3′(reverse). All reactions were incu-
bated in a 48 well plate at 95°C for 10 min, followed by 40
cycles of 95°C for 15 seconds, and 60°C for 1 min and per-
formed in triplicate. The U18 or GAPDH gene was used
as a control to normalize any differences in the total RNA
levels in each sample. A threshold cycle (CT) was observed
in the exponential phase of amplification, and quantifica-
tion of relative expression levels was performed using
standard curves for target genes and the endogenous con-
trol. Geometric means were used to calculate the ΔΔCT
(delta-delta CT) values and expressed as 2
-ΔΔCT. The value
of each control sample was set at 1 and was used to calcu-
late the fold-change of target genes.
Western Blotting
Ten μg of the protein were separated on NuPAGE®
Novex® Bis-Tris Mini Gels (Invitrogen, Carlsband, CA)
and transferred onto a nitrocellulose membrane (Invi-
trogen, Carlsband, CA). Mouse monoclonal antibody
against a partial recombinant IRAK1 (Abnova, Tai-
wan) and rabbit polyclonal anti-actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) were used as
primary antibodies. Anti-mouse goat IgG (MP Biome-
dicals, LLC, Santa Ana, CA) for IRAK1 and anti-rabbit
goat IgG (MP Biomedicals, LLC, Santa Ana, CA) for
actin were used for secondary antibodies. Band detec-
tion was performed using the enhanced chemilumines-
cence reagent, ECL Western Blotting Detection
Reagents (GE Healthcare UK Ltd, Little Chalfont,
Buckinghamshire).
Immunohistochemistry
Paraffin sections were deparaffinized through xylene for
three changes of five minutes each, followed by graded
alcohol immersions to water and phosphate buffered
saline solutions, the sections were treated with the
retrieval solutions (DAKO, Dakocytomation Inc.,Copin-
teria,CA,USA) for 20 minutes at 95°C. Next, the sections
were depleted of endogenous peroxidase by incubation
with 0.3% H2O2 in absolute methanol for 15 minutes.
After blocking nonspecific biding with blocking reagent
for 30 minutes, the sections incubated with primary
antibody at appropriate dilutions for overnight at 4°C.
For primary antibodies, monoclonal rabbit anti-human
antibody against IL-17 (Santa Cruz Biotechnology,Inc,
CA,USA). The sections were washed and incubated with
biotinylated goat anti-mouse (Sigma, Saint Louis,
Missouri, USA) for 1 hour at room temperature, then,
washed and incubated with avidin-biotinylated horserad-
ish peroxidase complex (ABC) and diaminobenzidine
tetrahydrochloride (DAB; Dakocytomation Inc.,Copin-
teria,CA), and counterstained with Mayer′s hematoxylin.
The negative control was prepared in the same manner
except that the primary antibody was omitted.
Double staining combining in situ hybridization and
immunohistochemistry
After deparaffinization, each section was fixed in 4%
paraformaldehyde for 10 minutes at room temperature,
washed 3 times in phosphate buffered saline (PBS) for
3 minutes, and subsequently treated with 600 g of pro-
teinase K for 10 minutes at room temperature. After
treatment in 0.2% glycine-PBS for 10 minutes, the sec-
tions were refixed in 4% paraformaldehyde for 10 min-
utes, washed 3 times in PBS for 3 minutes each, and
acetylated with 0.25% acetic anhydride in 0.1M trietha-
nolamine hydrochloride for 10 minutes. After washing
in PBS for 30 minutes, sections were prehybridized for
1 hour at 65°C with prehybridization buffer (50% forma-
mide and 5 saline-sodium citrate [SSC]). Hybridization
with DIG-labeled riboprobes of miR-146a (B-Bridge
International, Mountain View, CA) was performed over-
night at 65°C in hybridization buffer (50% formamide,
5X SSC, 5X Denhardt’ss o l u t i o n ,a n d2 5 0g / m lo f
Baker’s yeast transfer RNA). After hybridization, sections
were washed in 5X SSC for 30 minutes at 65°C, 0.2 SSC
for 2 hours at 65°C, and 0.2X SSC for 5 minutes at
room temperature. Blocking was performed overnight at
4°C with 4% horse serum and alkaline phosphatase-con-
jugated Fab anti-DIG antibody (Roche) in 1% sheep
serum. Staining was performed using BCIP and nitro-
blue tetrazolium (NBT; Roche). Thereafter, the sections
were washed in PBS and then were treated for 20 min-
utes at 90°C with retrieval solutions (Dakocytomation
Inc., Copinteria,CA). After blocking for 30 minutes, the
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at appropriate dilutions for 1 hour at room temperature.
After washing, the sections were incubated with Alexa
Fluor 594 conjugate(Invitrogen, Carlsbad, CA) for
30 minutes at room temperature, washed, and then
incubated with 4, 6-diamidino-2-phenylindole (Dojindo
Laboratories, Kumamoto, Japan). The negative control
was prepared in the same manner, but without the
primary antibody.
Statistical analysis
The Mann-Whitney U test was used to compare the
gene expression between two groups. A one-way analy-
sis of variance (ANOVA) followed by Tukey’sp o s th o c
analysis was used to compare gene expression between
the three groups. P values less than 0.05 were consid-
ered to be statistically significant. All statistical analyses
were performed on a personal computer using the Stat
View version 5.0 statistical software package (Abacus
Concepts, Berkeley, CA).
Results
Six miRNAs up-regulated in IL-17 producing T cells in
microarray analysis
The microarray analysiso ft h ee x p a n d e dI L - 1 7
producing T cells identified six miRNAs that were sig-
nificantly up regulated during the differentiation of the
IL-17 producing T cells(The Center for Information
Biology Gene Expression Database, CIBEX; http://cibex.
nig.ac.jp. CIBEX Accession : CBX133.). The six miRNAs
were miR-26a (1.81 fold; p = 0.029), 146a (1.43 fold;
p = 0.040), 146b (1.80 fold; p = 0.040), 150 (1.61 fold;
p = 0.040), 155 (2.03 fold; p = 0.007) and let-7a (2.12
fold; p = 0.012; Table 2). There was no miRNA that was
significantly down regulated in the differentiation of IL-
17 producing T cells. The expression of let-7a, miR-26a,
146a,b, 150, and 155 between expanded IL-17 producing
T cells and non-expanded cells was compared by using
real-time PCR to confirm the results of microarray
analysis. The expression level of these six miRNAs in
expanded IL-17 producing T cells was significantly
higher than in CD4+ T cells. MiR-146a and miR-146b
increased by a factor of six in comparison to non-
expanded cells. The expansion of miR-155 was the
greatest (9-fold), and the lowest was miR-26a (Figure
1A). Real-time PCR was performed to examine the
expression of the important factors in the differentiation
of human Th17 cells, including Foxp3, RORgt, IRAK1,
and SOCS1. The expression level of RORgt, and SOCS1
in expanded IL-17 producing T cells was significantly
higher than in non-expanded cells, while Foxp3 in CD4
+ T cells was strongly expressed than in expanded IL-17
producing T cells. There was no significant difference in
the expression of IRAK1between CD4+ T cells and
expanded IL-17 producing T cells (Figure 1B). However,
western blotting revealed that IRAK1 was down regu-
lated in expanded IL-17 producing T cells in protein
level (Figure 1C).
RA patient PBMCs exhibit increased expression of Let-7a,
miR-26a, 146a,b, 150, and 155
The expression pattern of the six miRNAs in PBMC
form RA, OA and healthy subjects were analyzed using
real-time PCR to determine whether the miRNA identi-
fied by microarrays analysis were expressed in RA
patients in comparison to OA and healthy subjects,. The
expression level of miR-26a, miR-146a/b, miR-150 and
miR-155 in RA patients were significantly higher than in
healthy subjects. However, there were no significant dif-
ferences between RA and OA patients in the expression
level of miR-26a, miR-146b. There were significant dif-
ferences between RA and OA patients in the expression
level of miR-146a, miR-150 and miR-155. There was no
significant difference in the expression level of Let-7a
between RA, OA patients and healthy subjects (Figure
2A). Real time PCR of IL-17 was used to examine the
relationship between the expression level of six miRNAs
and IL-17 in RA patients. The expression level of miR-
146a was similar to that of IL-17. Patient RA1 and RA4
had high disease activity, although the Larsen grade was
low. The expression level of miR-146a and IL-17 in
patient RA1 and RA4 was high in comparison to the
other patients. miR-146a expressed intensely with IL-17
expression in PBMC from the patients with early stage
of RA and high disease activity (Figure 2B).
The synovium from RA patients exhibit increased
expression of miR-146a,b, 150, and 155
RA pathogenesis is characterized by synovial inflamma-
tion, secretion of inflammatory cytokines including
IL-17 and subsequent joint destruction. Therefore, the
expression pattern of miR-146a/b, miR-150, and miR-
155 in the synovium of RA patients was examined using
Table 2 Six miRNAs up-regulated in IL-17 producing
T cells in microarray analysis
miRNA ID Expression ratio p value
6 miRNAs up-regulated let7a 2.119413042 0.01219878
hsa-miR-26a 1.812510994 0.02939706
hsa-miR-146a 1.43106906 0.04019598
hsa-miR-146b 1.802918862 0.03959604
hsa-miR-150 1.605962505 0.04019598
hsa-miR-155 2.025291111 0.00719928
For the identification of miRNA in differentiating IL-17 producing cells, miRNA
microarrays (NCode microarray, Invitrogen) were performed. Six miRNAs were
significantly up regulated in the differentiation of the IL-17 producing T cells.
There was no miRNA that significantly down regulated in the differentiation
of IL-17 producing T cells. (The Center for Information Biology Gene
Expression Database, CIBEX; http://cibex.nig.ac.jp. CIBEX Accession : CBX133.)
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155 were expressed intensely in RA in comparison to
OA. There was a significant difference between RA and
OA. The expression of miR-146a and miR-146b tended
to increase with high disease activity, which was consis-
tent with previous reports[24,25]. In particular, miR-150
was highly up regulated in the synovium of patients
RA7, RA10 and RA11, (Figure 3A). Patient RA7 and
RA11 were poor controlled with severe joint destruc-
tion. Patient RA10 had long disease duration subse-
quently severe joint destruction (Figure 3B). The disease
activity in the synovium was analyzed histologically
using IL-17 immunohistochemistry. The synovium with
high expression of miR-146a, miR-146b, miR-150 and
miR-155 showed vigorous proliferation of synovial cells
and infiltration of inflammatory cells and abundant
IL-17 positive cells. The analysis of the synovium from
RA and OA patients revealed that miR-146a/b, miR-150
and miR-155 were highly expressed in RA synovium
with hyperplasia and infiltration of inflammatory cells
including Th17 producing cells in poorly controlled
patients with severe joint destruction (Figure 4A).
MiR-146a expressed in IL-17 producing cells
MiR-146a was previuosly reported to be expressed in
the T cells in the RA synovium [25]. We therefore con-
firmed whether miR-146a expressed in the IL-17
producing T cells using the double staining of in situ
hybridization and immunohistochemistry of IL-17. MiR-
146a expression was mainly observed in the superficial
and sublining layers as previuosly described [25]. In
addition, IL-17 was seen in the RA synovium, while it
was not seed in OA synovium. Double staining revealed
that miR-146 + cells merged IL-17, thus indicating miR-
146a to be expressed in IL-17 producing T cells
(Figure 4B).
Discussion
Recently, a potential link between miRNA and several
human diseases has been revealed. For example, the
expression of let-7 has been shown to be lower in lung
cancer tissue than in normal lung tissue, and such
down-regulation may promote high levels of expression
of the Ras gene [30]. In addition, the expression of miR-
143 and miR-145 is reduced in colon cancer tissue. Evi-
dence of miRNA function in conditions such as leuke-
mia, viral infection, and DiGeorge syndrome has been
reported [31,32]. Recent reports have suggested that sev-
eral miRNA might participate in the pathogenesis of RA
[21,24-26].
miRNAs have been investigated because of their poten-
tial clinical application for therapeutic methods. Thera-
peutic trials aimed at silencing miRNA in vivo have
been conducted [32,33]. Tazawa et al. demonstrated that
Figure 1 A quantitative PCR analysis of the expression of six miRNAs, Foxp3, RORgt, IRAK1, and SOCS1. A, A quantitative PCR analysis of
the expression of let-7a, miR-26a, 146a,b, 150, and 155 in expanded IL-17 producing T cells and non-expanded cells. The expression level of
these six miRNAs in expanded IL-17 producing T cells was significantly higher than in non-expanded cells. MiR-146a and miR-146b have
increased by a factor of six in comparison to non-expanded cells. miR-155 showed a 9-fold increase, and miR-26a showed the smallest increase.
B, A quantitative PCR analysis of the expression of Foxp3, RORgt, IRAK1, SOCS1. The expression level of RORgt, and SOCS1 in expanded IL-17
producing T cells significantly was higher than in non-expanded cells, while Foxp3 in expanded cells was significantly down regulated in
comparison to non expanded cells. There was no significant difference in the expression of IRAK1. C,Western blotting of IRAK1. IRAK1 was down
regulated in expanded IL-17 producing T cell in protein level.
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Page 6 of 11miR-34a is down-regulated in human colon cancer, and
that tumor growth in mice is significantly inhibited by
the local injection of synthetic double stranded miR-34a
in vivo [34]. The intra-articular injection of double
stranded miR-15a successfully induced cell apoptosis by
inhibiting the translation of BCL2 protein in the syno-
vium in arthritic mice. This suggested that the intra-
articular injection of synthetic miRNAs can regulate the
endogenous miRNAs in arthritic synovia [35]. The dis-
covery of a new lineage of CD4+ effecter T helper (Th)
cells that selectively produce IL-17 in mice has provided
exciting new insights into immune regulation, host
defense, and the pathogenesis of autoimmune and other
chronic inflammatory disorders. Although IL-17 plays a
crucial role in RA pathogenesis, the differentiation
mechanism of human Th17 cells from CD4+ T cells is
unclear. MiRNAs are reported to be a important factor in
the differentiation of T cells [ 3 6 ] .T h e r e f o r e ,i d e n t i f i c a -
tion of miRNAs in Th17 cell differentiation could eluci-
date a new mechanism of RA pathogenesis, subsequently
lead a novel therapeutic approach to the RA. In the cur-
rent study, IL-17 producing T cells were expanded from
PBMCs from healthy volunteers and the expression pat-
tern of miRNAs in the differentiation of IL-17 producing
Figure 2 A quantitative PCR analysis for the expression of six miRNAs in PBMC. A, A quantitative PCR analysis for the expression of six
miRNAs in PBMC in RA, OA patients and healthy volunteer. The expression level of miR-26a, miR-146a/b, miR-150 and miR-155 in RA patients
were significantly higher than in healthy subjects. There were no significant differences between RA and OA patients in the expression level of
miR-26a, miR-146b. Between RA and OA patients, significant differences were observed in the expression level of miR-146a, miR-150 and miR-
155. B,. B., quantitative PCR analysis to examine the relationship between the expression level of Let-7a, miR-26a, 146a/b, 150, and 155 and IL-17
in RA patients. IL-17 and miR-146a was more intensely expressed in patient RA1, RA2 and RA4 than patient RA3,RA5,RA6 and OA1.
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demonstrated that let-7a, miR-26a, 146a,b, 150, and 155
were significantly upregulated in the differentiation of
IL-17 producing cells. There are several reports about
Foxp3, RORgt, IRAK1 and SOCS1in the differentiation of
IL-17 producing T cells. Foxp3 is the transcription factor
controlling regulatory T cell development[37], while,
RORgt is the master regulator that directs the differentia-
tion program of Th17 cells [38]. The expression level of
RORgt in expanded IL-17 producing T cells was signifi-
cantly higher than in non-expanded cells, while Foxp3
was expressed more strongly in non-expanded cells in
comparison to expanded cells, indicating that the IL-17
producing T cells were expanded. IRAK1 and SOCS1 not
only play a crucial role in Th17 cell differentiation, but
also are regulated by miR-146a/b and miR-155 respec-
tively [39,40]. In the current series, the expression level
of SOCS1 in expanded IL-17 producing T cells was
significantly higher than in non-expanded cells. There
was no significant difference in the expression level of
IRAK1 between the expanded and non expanded cells at
the mRNA level. However IRAK1 protein was decreased
in the expanded cells, which suggested miR-146a/b might
inhibit the translation to IRAK1 protein from mRNA.
MiR-146a was expressed intensely with IL-17 expres-
sion in PBMC from the patients with early stage of RA
and high disease activity. miR-146a/b was associated
with high disease activity, and miR-150 was intensely
expressed in the patients with severe joint destruction.
MiR-150 has not been associated with the high expres-
sion of miR-146 and miR-155 in PBMC and synovium
of RA in previous reports [24-26]. MiR-150 might also
p l a yar o l ei nR Ap a t h o g e n e s i s .T h ee x p r e s s i o no fm i R -
146a and IL-17 was high in PBMC in patients with low
score of Larsen grade and short disease duration in the
current series. A patient with a high score of Larsen
grade and long disease duration showed a low expres-
sion level of miR-146a, while that of miR-150 was high.
Therefore, the high expression of miR-146a in PBMC
was strongly associated with IL-17 expression, especially
Figure 3 A quantitative PCR analysis for the expression of miRNAs in synovium. A, A quantitative PCR analysis for the expression level of
miR-146a/b, miR-150, and miR-155 in synovium of RA and OA patients. All miRNAs were intensely expressed in RA synovium in comparison to
OA. B, miR-146a and miR-146b tended to be express intensely in high disease activity. miR-150 was highly up regulated in synovium in patients
RA7, RA10 and RA11.
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high disease activity was associated with the expression
of miR-150 in the synovium. The number of patients in
the current study was small, therefore, further examina-
tion is necessary to clarify the relationship between
these miRNAs and disease activity, including the expres-
sion level of IL-17. Our results revealed miR-146a to be
expressed in the IL-17 producing T cells. In a previous
report, accumulated CD3+ T cells were observed to
express miR-146, thereby suggesting that miR-146 might
play a role in the persistent inflammation in RA via a
T cell network, which strongly supports that miR-146a
thus expressed in Th17 cells [25].
The current results suggested that miR-146a/b, miR-
150 and miR-155 might play a role in IL-17 producing
T cells differentiation and these miRNAs were expressed
intensely in the PBMC and synovium in RA patients in
comparison to OA patients and healthy subjects. In
addition, the miR-146a expression in the IL-17 produ-
cing T cells of the RA synovium was confirmed. In the
Figure 4 Immunohistochemistry and double staining combining in situ hybridization.A ,R e p r e s e n t a t i v eh i s t o l o g yo fR Aa n dO Ab y
immunohistochemistry of IL-17. RA synovium with high expression level of miR-146a/b, miR-150 and miR-155 demonstrated amount IL-17
positive cells in hyperplasia synovium while OA synovium had few IL-17 positive cells in the fibrous tissue. Original magnification 100×. Bar
indicates 100 μm. B, Double staining for the in situ hybridization and immunohistochemistry of rheumatoid arthritis (RA) and osteoarthritis
synovial tissue. In situ hybridization (ISH) for mature microRNA146-a (miR-146a) and immunohistochemistry with IL-17 antibodies were performed
on synovial tissue specimens obtained from patient RA7 and OA3. Mature miR-146a was expressed in the cells of the superficial and sublining
layers, thus including IL-17 positive cells. The arrows in the merged images indicate the cells expressing miR-146a and IL-17 antibody. Staining of
the tissue sections with 4, 6-diamidino-2- phenylindole (DAPI) is shown at the right. (Original magnification X200).
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associated with IL-17 producing T cells. Changsheng Du
et al. reported that miR-326 regulates Th-17 differentia-
tion and associated with the pathogenesis of multiple
sclerosis[27]. These evidence suggested that the function
and analysis on the differentiation of IL-17 producing
T cells is not simple, and perhaps they were depending
on the disease variety, disease progression degree and
the disease stage. Indeed, previous reports demonstrated
that miR-146a/b, miR-150 and miR-155 are expressed in
PBMC or synovium in RA patients, which might include
miRNAs which are expressed in IL-17 producing
T cells. However, the function of these miRNAs in the
differentiation of IL-17 producing T cells was not eluci-
dated in the present study. Several target genes of these
6 miRNAs were validated[30,40-53] (Table 3). The pre-
dicted target genes for miRNAs are estimated to range
between one and several hundred, therefore, other target
genes might play a role in the differentiation of IL-17
producing cells as well as the validated target genes.
Further examination is needed to elucidate the function
of these miRNAs including the determination of their
target genes, which could lead to the development of
novel therapeutic strategies for the treatment RA.
Conclusions
These results indicated that miR-146a/b, miR-150 and
miR-155 were associated with IL-17 expression in the
PBMC and synovium in the RA patients, especially
expression of miR-146a in IL-17 producing cells was
comfirmed. Their altered expression in the stage and
activity of RA suggested that they might play a role in
the pathogenesis of RA via IL-17 expression. In addition,
our results should be developed the excessive analysis of
the function of these miRNAs in the RA to lead the
novel treatment.
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